Cargando…
Rethinking the INN system for therapeutic antibodies
In the context of a possible revision of the International Nonproprietary Names (INN) system of recombinant monoclonal antibodies, which is saturated, we propose several avenues of reflection driven by the primary goal of the INN, information of health-care professionals. Clinical considerations arg...
Autores principales: | Pottier, Jérémy, Chastang, Romane, Dumet, Christophe, Watier, Hervé |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240647/ https://www.ncbi.nlm.nih.gov/pubmed/27808597 http://dx.doi.org/10.1080/19420862.2016.1255520 |
Ejemplares similares
-
Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development
por: Dumet, Christophe, et al.
Publicado: (2019) -
The INNs and outs of antibody nonproprietary names
por: Jones, Tim D., et al.
Publicado: (2015) -
Rethinking Opsins
por: Feuda, Roberto, et al.
Publicado: (2022) -
Is there any revival of the use of plasma therapy or neutralizing convalescent antibody therapy to treat SARS-CoV-2 variants and are we rethinking preparedness plans?
por: Garraud, Olivier, et al.
Publicado: (2023) -
Harnessing Fc/FcRn Affinity Data from Patents with Different Machine Learning Methods
por: Dumet, Christophe, et al.
Publicado: (2023)